The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II clinical trial of talazoparib maintenance therapy in patients with triple-negative breast cancer who showed platinum-sensitivity on first- or second-line platinum-based chemotherapy: KCSG BR21-10.
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagan (Inst)
 
Min Hwan Kim
Consulting or Advisory Role - Boryung Pharmaceuticals; Daiichi Sankyo Pharmaceutical; Samsung Bioepis
Research Funding - AstraZeneca; Boryung Pharmaceuticals; Celltrion; Handok
 
Gun Min Kim
No Relationships to Disclose
 
Jee Hung Kim
No Relationships to Disclose
 
Han Jo Kim
No Relationships to Disclose
 
JIEUN LEE
No Relationships to Disclose
 
Yong Wha Moon
No Relationships to Disclose
 
Hee Kyung Ahn
No Relationships to Disclose
 
Hee Jun Kim
No Relationships to Disclose
 
Seong-Hoon Shin
No Relationships to Disclose
 
Moon Hee Lee
No Relationships to Disclose
 
Kyoung Eun Lee
No Relationships to Disclose
 
Hye Sung Won
No Relationships to Disclose
 
Seok Yun Kang
No Relationships to Disclose
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST
 
Kyong Hwa Park
No Relationships to Disclose